Good afternoon, ladies and gentlemen, and welcome to the Acacia Research Third Quarter Financial Results. At this time, all participants have been placed on a listen-only mode and the floor will be open for your questions and comments after the presentation. It is now my pleasure to turn the floor over to Rob Fink. Sir, the floor is yours.

Thank you, operator. Hosting the call today are Clifford Press, Chief Executive Officer; and Richard Rosenstein, Chief Financial Officer. Before beginning, I would like to remind you that the information provided during this call may contain forward-looking statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally relate to the company’s plans, objectives, and expectations for future operation and are based on current estimates and projections, future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties. For a discussion of such risks and uncertainties, please see the Risk Factors described in Acacia’s Annual Report on Form 10-K and quarterly reports on Form 10-Q that are filed with the SEC. I’d like to remind everyone that a press release disclosing the company’s financial results was issued this afternoon after the close of market. This release may be accessed on the company’s website at acaciaresearch.com under the News and Events tab. With all that said, now I would like to turn the call over to Clifford Press. Clifford, the call is yours.

Thank you, Rob. Good afternoon, everyone. This has been an active period for Acacia. During the quarter, we essentially completed our planned monetization of the Woodford life sciences portfolio with the IPO of Oxford Nanopore Technologies at the end of September on the London Stock Exchange. Oxford Nanopore is the largest single position in that portfolio and we were the fourth largest shareholder pre-IPO. As a result of the IPO, we recognized nearly $120 million in realized and unrealized gains for the quarter. Acacia sold approximately 10% of its position in this IPO, generating net proceeds of approximately $22 million and our remaining position represent just over 35 million shares was valued at $267.8 million at September 30, 2021. We have entered into a six-month lockup for our remaining shares. And because of this agreement, we are valuing our remaining position at a slight discount until the expiry of the lockup. We've now recovered $256 million of our original $282 million investment in this life science portfolio. As of September 30, we held positions in four public companies including Arix Biosciences, Immunocore and Oxford Nanopore, valued at $348.7 million. We also continue to hold meaningful positions in three private life sciences companies and we believe there is significant potential for these companies. Looking ahead, we are actively working to complete acquisitions of companies through a tightly coordinated research process, leveraging our team's experience in public and private markets, with a seasoned Board of Directors. We focus on mature technology, life sciences, healthcare and industrials and certain segments of the financial services area, including insurance. Our primary opportunity set remains with companies that are under $2 billion in equity market cap. As we have said in the past, we view this segment as the least efficient area in the public markets…

Thank you, Clifford. First, I'd like to note that the acquisition of Printronix closed in early October, subsequent to the end of the quarter. Accordingly, the results reported today do not include any contribution from this business nor reflect the $33 million in cash paid for this business. Our GAAP book value at September 30th, 2021 was $235.9 million or $4.82 per basic share compared to $292.5 million or $5.94 per basic share at December 31stm 2020. As a reminder, our GAAP book value includes the impact of our warrant and embedded derivative liabilities on our balance sheet which in turn reflect the impact of the increase in the company's share price over the last year. As these liabilities would be extinguished upon exercise or expiration of these warrants and convertible preferred stock, we think it is more useful to consider our book value should all of these instruments be fully converted. On this basis, assuming full exercise of all issued derivatives, Acacia's pro forma book value would rise to $1 billion or $6.31 per share, up from $942.8 million or $5.70 per share as of June 30th, 2021 and $882.5 million or $5.39 per share on the same basis as of December 31st, 2020. For the quarter, highlights of our financial performance include the following: revenues for the quarter were -- for the third quarter of 2021 were $1.6 million compared to $19.5 million a year ago. Operating loss was $12.7 million in the quarter compared to a loss of $2.8 million a year ago. Realized and unrealized gains totaled $104.2 million in the quarter. Cash and equity securities at fair value totaled $605.1 million at September 30, 2021 compared to $274.6 million at December 31, 2020. And debt was $182.9 million in senior secured notes issued to Starboard Value LP. More detail on these results have been made available in the press release issued just after the close and then our quarterly report on Form 10-Q which we filed with the SEC just after the close as well. Now let me turn the call back to Clifford for closing comments. Clifford?

Thanks, Rich. In conclusion, during this quarter several facets of our strategy came into focus. Acacia is uniquely positioned -- is a uniquely positioned acquirer of businesses and a compelling counterparty. Our focus continues to be on improvement in our underlying net asset value and executing our acquisition strategy. And we would now be happy to answer any questions.

Certainly. The floor is now open for questions. Your first question is coming from Anthony Stoss. Please announce your affiliation and pose your question.

Hi. Anthony Stoss, Craig-Hallum. Hey, Clifford, Rich.

Hey, Tony.

Hey, Tony.

I'm not sure how much you'll be able to say, but with both Spok and maybe Comtech is too early on are things progressing at kind of the rate that you would have expected? And I know you're limited at what you can say, I'm just curious from a timing perspective, if you can shed some light on how much lag you think that will go. And the easier one for Rich the G&A was up quite a bit. You've been chugging along a little over $6 million and the bounce to $10.3 million. I know you had a bunch of M&A transactions during the quarter. Where do you think OpEx or G&A should look for the December quarter?

Why don't you answer that first Rich and then I'll comment on the transactions.

Sure. Thanks, Tony. So from a headcount perspective, we really have not increased significantly our headcount since the last quarter. So the expenses that you're seeing really relate to the deals that we're working on and expenses incurred and diligencing deals and pursuing those deals. So that's going to be a function in each quarter of how active we are in diligencing and working through our execution process. So I don't want to give a specific number for the fourth quarter because we're actively involved in a couple of situations right now as you know and then others that we continue to work on. But that's going to vary quarter-to-quarter based upon our level of activity in our acquisition pipeline.

Thanks, Rich. And Tony with regard to your first question about the two offers that we've made those are obviously public company offers. And it remains to be seen what happens there. I would say that we have not been surprised by any of the developments to date in either of those situations. I think the trading price of both of those securities relative to the offer is probably the best indication of how things are going.

Okay. Just to follow up on your comment Clifford on the Samsung Wi-Fi patent license. Clearly, Wi-Fi 6 is going to be huge. I would presume that you maybe give a notice to other companies, or how do you think this will play out with other customers? And then maybe a similar question on the Ethernet patent side, I think, you guys had disclosed a license with Cisco I believe. I'm curious if you made any progress with other customers there as well.

As you know in the IP business the first license is very important. We have had a long-standing relationship with Samsung in the past and we think this is critical transaction for monetizing this portfolio and as for the future Samsung is one of first of a very, very long list of companies to whom these patents would apply. So, I think, we expect to now proceed and license these patents to the remaining users. Similar story on the Ethernet patents, we pay a lot of attention to our first counterparty as does the industry and it's an indication of where things go from there.

Okay. And maybe if I could sneak in one more here for Rich. On Printronix as it closed after the quarter can you maybe help us understand revenue profitability OpEx headcount that you'll be incurring here in the December quarter?

Yes. What I can say about Printronix is and we mentioned at the time it was a $33 million acquisition and we said that we paid approximately 3.5 times EBITDA. So that will give you a sense of the profitability a bit under $10 million. And we'll have a lot more to say about it in the fourth quarter when we will include their results within our own.

Okay. Thanks, Rich.

Thanks, guys. Good luck.

Thank you, guys.

Your next question is coming from Brett Reiss with Janney Montgomery Scott. Please post your question.

Thank you, operator. Hi, Clifford. Hi, Richard.

Hello, Brett.

Hey, Brett.

Hi. The NOL was about $285 million and you booked $100 million plus in realized gains from the Woodford portfolio. So is the NOL now down to about $185 million? Is that the way that works?

Not exactly. So you're right we had between net operating loss carryforwards and capital loss carryforwards. At the end of 200 and – $285 million of both combined. We have sold and realized some gains during the course of the year including in the third quarter when we sold a small part of our Oxford Nanopore position and we sold another position in the -- during the quarter which is a part of our ownership of Immunocore. And so we did recognize some gains, but the $100 million that you're referencing is actually our realized and unrealized gains. So the impact on our NOL the use of our NOL really relates only to the realization of gains not unrealized. So it's quite a bit less than the full $100 million.

Okay. So because the NOL is still material and in place the blocker provision that would prevent Starboard from exercising their warrants is also still at play?

The document speaks for itself Brett, and the blocker is in the document, it's not tied to the existence of the NOL.

Okay. Now the $605 million in cash, on the balance sheet in the release you show $217.9 million in cash and equivalents. And then there's a line item equity securities at fair value. Is that treasury bills? Is that part of the cash?

No. No, no. Those are – think of those as the marketable securities. So those are the publicly traded securities at $387 million.

Okay. So with the other 400 – when you say you have $605 million in cash where is that?

No, it's cash and equity investments.

And equity okay.

It's cash and marketable securities, Brett.

Got it. Got it. Got it. Sorry about that. Now you mentioned, you filed that you own securities in SPOK, but I've not seen a filing on the SMTL. But in your remarks you indicated that you did buy securities in – well, do you own some of the SMTL and you just haven't filed?

Well, as you know, Brett the filing threshold is 5%. So we're obviously under 5% in our ownership.

Okay. I'll – thank you for answering for my questions. I’ll drop back in queue, if there maybe others on the call.

Thanks, Brett.

There appear to be no further questions in queue at this time. I'd like to turn the floor back over to Clifford Press for any closing comments.

Clifford?

Sorry. Thank you very much for attending. We look forward to explaining the rest of the Acacia strategy, as it comes into focus going forward. As you know, it's been a while to prepare and assemble the company to start executing, and we think that the best way to make it clear what our strategy is will be to demonstrate by example and execute on transactions. We look very much forward to having that happen and being able to report on that as we proceed.

Okay. Thank you all for joining us today. Operator?

Thank you, ladies and gentlemen. This does conclude today's conference call. You may disconnect your phone lines at this time, and have a wonderful day. Thank you for your participation.